Idiopathic Membranous Nephropathy Clinical Trial
Official title:
Study on the Application of Hyperspectral Imaging Technique in the Treatment of TAC
We propose hyperspectral imaging analysis as a method to identify the efficacy of hormone-tacrolimus therapy for PMN, and to classify sensitive and insensitive patients treated with hormone-tacrolimus regimen. A variety of machine learning models were used to prove that hyperspectral imaging technology could assist patients in selecting the optimal treatment plan, and further explore the predictive indicators of PMN treatment effect.
Renal biopsy slides of patients with idiopathic membranous nephropathy diagnosed by renal biopsy in our hospital from February 2016 to February 2022 were collected. ENVI Classic software was used to process the hyperspectral images and delineate the region of interest. The one-dimensional spectral data of each pixel in each region were derived. Machine learning and deep learning methods were used to analyze the characteristics of hyperspectral data and classify them. The data of the previous study came from the Department of Pathology and Nephrology of Qianfoshan Hospital in Shandong Province. Under the light microscope, electron microscope and immunofluorescence microscope, the pathological types of glomerular diseases in patients with proteinuria were identified. By scanning the corresponding patient's H&E stained pathological sections, the hyperspectral microscopic images were classified by machine learning and deep learning methods, and the classification accuracy was greater than 85%. It was concluded that hyperspectral imaging technology can be used as a non-invasive diagnostic method to predict treatment response. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06245707 -
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy
|
N/A | |
Recruiting |
NCT03864250 -
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy
|
N/A | |
Completed |
NCT01845688 -
Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy
|
N/A | |
Completed |
NCT01180036 -
MEmbranous Nephropathy Trial Of Rituximab
|
Phase 2/Phase 3 | |
Withdrawn |
NCT01093781 -
Aliskiren in Patients With Idiopathic Membranous Nephropathy
|
N/A | |
Completed |
NCT00362531 -
Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT05839314 -
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
|
Phase 4 | |
Completed |
NCT00302523 -
Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy
|
N/A | |
Terminated |
NCT03466801 -
The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.
|
N/A | |
Terminated |
NCT03475602 -
Membranous Nephropathy-associated Serological Antibody Predict the Prognosis of Idiopathic Membranous Nephropathy
|
||
Not yet recruiting |
NCT05850845 -
Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
|
||
Not yet recruiting |
NCT05667883 -
Prognostic Model of GC/CTX in the Treatment of MN
|
||
Not yet recruiting |
NCT05667922 -
Prognostic Model of TAC in the Treatment of MN
|
||
Not yet recruiting |
NCT05667909 -
Prognostic Model of Rituximab in the Treatment of MN
|
||
Not yet recruiting |
NCT05667896 -
Prognostic Model of GC/TAC in the Treatment of MN
|
||
Recruiting |
NCT02173106 -
A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy
|
Phase 2 | |
Completed |
NCT01161459 -
Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
|
N/A | |
Recruiting |
NCT03549663 -
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)
|
N/A | |
Not yet recruiting |
NCT05845762 -
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy
|
||
Completed |
NCT00694863 -
Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy
|
Phase 2 |